An evaluation of the safety and tolerability of different doses of Recombinant Anti HER2 for injection (open study section) HL02 in Chinese healthy male subjects compared HL02 with Herceptin ? the pharmacokinetics, safety ,tolerability and immunogenicity, randomized, double-blind, Comparative study of pharmacokinetics clinica

Trial Profile

An evaluation of the safety and tolerability of different doses of Recombinant Anti HER2 for injection (open study section) HL02 in Chinese healthy male subjects compared HL02 with Herceptin ? the pharmacokinetics, safety ,tolerability and immunogenicity, randomized, double-blind, Comparative study of pharmacokinetics clinica

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs HL-02 (Primary) ; Trastuzumab
  • Indications Breast cancer; Male breast cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top